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Abstract
The effect of metabolites accumulating in phenylketonuria (PKU) was investigated on carnitine metabolism in rats and in
patients with PKU. Of phenylacetic acid (PEAA), phenylpyruvic acid and homogentisic acid the PEAA was found to be the
most effective in inhibiting carnitine biosynthesis in rats. Following 60 min, a single intraperitoneal dose of PEAA the
relative conversion rate, i.e. the hydroxylation, of tracer [Me-3H]butyrobetaine to [Me-3H]carnitine decreased from
62.2 þ 6.00% to 39.4 þ 5.11% (means þ S.E.M., P6 0.01) in the liver, in the only organ doing this conversion in rats. The
conversion of loading amount of unlabeled butyrobetaine to carnitine was also markedly reduced. The impaired
hydroxylation of butyrobetaine was reflected by a reduced free and total carnitine levels in the liver and a reduced total
carnitine concentration in the plasma. PEAA decreased the hepatic level of glutamic acid and K-ketoglutaric acid (K-KG),
suggesting a mechanism for the reduced flux through the butyrobetaine hydroxylase enzyme, because K-KG is an obligatory
co-enzyme. In the plasma and urine of PKU patients on unrestricted diet, markedly decreased total carnitine levels were
detected. In the liver of PEAA-treated rats and urine of PKU patients, a novel carnitine derivative, phenacetyl-carnitine was
verified by HPLC and gas chromatography-mass spectrometry. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
L-(3)Carnitine, (3-OH-4-N-trimethylaminobuty-
rate) is an obligatory factor for the mitochondrial
L-oxidation of long-chain fatty acids [1,2]. All mam-
mals are able to synthesize carnitine in a well-estab-
lished metabolic pathway [3^6]. The last step of the
biosynthesis is a stereospeci¢c hydroxylation of Q-bu-
tyrobetaine (4-N-trimethylaminobutyrate) to L-carni-
tine by the butyrobetaine hydroxylase (EC 1.14.11.1)
enzyme. The enzyme is located in rats exclusively in
the liver, and in man, in the liver and kidney, render-
ing these organs the carnitine suppliers for the or-
ganism [7]. The enzyme needs K-ketoglutarate (K-
KG) as co-enzyme [5] and ascorbic acid as co-factor
under both in vitro and in vivo conditions [8,9].
Human carnitine de¢ciencies are classi¢ed as being
primary [10] and secondary according to their origin.
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Some of the latter class are associated with organic
acidurias, whilst others are arti¢cial, mostly caused
by pharmacological treatment [11]. Earlier, we estab-
lished that valproic acid, an anticonvulsive drug
(known to cause carnitine de¢ciency), inhibited car-
nitine biosynthesis in rats by reducing the conversion
of buryrobetaine to carnitine in the liver. This im-
paired £ux through butyrobetaine hydroxylase was
attributed to the lowered L-glutamate and K-KG lev-
els [12]. In that work [12], we found that benzoic acid
also inhibited carnitine biosynthesis in a similar man-
ner. This latter observation is in a good accordance
with a recent report that benzoate therapy causes
carnitine de¢ciency [13,14]. This ¢nding led us to
search whether other benzoic acid analogue aromatic
compounds, metabolites or drugs, can also inhibit
carnitine biosynthesis.
The metabolites of pathological phenylalanine ca-
tabolism are compounds containing aromatic ring
and carrying clinical interest: they accumulate in a
human diseases caused by defective phenylalanine
degradation. One of these diseases is the phenylketo-
nuria (PKU), in which the conversion of phenylala-
nine to tyrosine, catalyzed by the phenylalanine hy-
droxylase (PAH, EC 1.14.16.1), is defective or
missing, resulting in the accumulation of phenylala-
nine and its degradation products, such as phenyl-
acetic acid (PEAA) and phenylpyruvate. PKU is the
most serious form of the defective degradations be-
cause the accumulating phenylalanine [15] causes
mental retardation [15,16]. To date, many types of
mutation of the PAH gene have been described, and
the possibility of gene therapy [17,18] and the rela-
tionship to other metabolic pathways [19] have been
intensively studied. In the present work, we have
established that PEAA inhibited carnitine biosynthe-
sis in rats and identi¢ed of a novel metabolite, phe-
nacetyl-carnitine (PEAC) in the liver of PEAA-
treated rats and in the urine of PKU patients.
2. Materials and methods
2.1. Materials
Phenylacetic acid, phenylpyruvic acid, homogenti-
sic acid, 4-(dimethylamino)butyric acid (nor-butyro-
betaine), (3-carboxypropyl)trimethyl-ammonium
chloride (butyrobetaine), phenacetyl chloride, coen-
zyme A (CoA), heptanesulfonic acid and other ¢ne
chemicals and enzymes were purchased from Sigma-
Aldrich (Budapest, Hungary). [1-14C]Acetyl-CoA,
[3H]methyl iodide were from Amersham (Little Chal-
font, UK). L-Carnitine was a kind gift from Sigma-
Tau (Rome). Acetyl-CoA was prepared from acetic
anhydride and CoA as described [20]. Acetyl-carni-
tine and PEAC standards were prepared from L-car-
nitine and acetyl chloride and phenacetyl chloride,
respectively, as described [21], with the modi¢cation
that in the preparation of PEAC, tri£uoroacetic acid
was used as solvent.
[Me-3H]Butyrobetaine with approximately 106
cpm/nmol speci¢c activity was synthesized from
nor-butyrobetaine and [3H]methyl iodide as de-
scribed [22]. L-carnitine as authentic standard was a
kind gift from Sigma-Tau (Rome), while L-carnitine
for treatment of PKU patients was Pro-Carn from
4 Life Products (Farmington, CT, USA).
2.2. Subjects
PKU patients on mixed diet without any food re-
striction were selected for the study. Their plasma
phenylalanine levels ranged between 20 and 50
mg% as determined by the Guthrie assay. Carnitine
levels were determined in the plasma and urine of 19
patients (ten male, nine female) aged between 19 and
32 years. To detect PEAC, the urine and plasma of
another group of patients (three male and four fe-
male, two of them from the former group) were an-
alyzed. The latter patients were supplemented with
daily 1 g L-carnitine orally for 10 days and the anal-
yses were performed before and after carnitine sup-
plementation. only 24-h urine collections were used.
The amount of urine was between 1200 and 1900 ml
in the most cases. Five more patients on strict diet
were also involved for serum carnitine determination.
2.3. Animals and treatments
Male Wistar rats weighing 200^250 g were used.
The experiments were performed between 09.00 and
12.00 h. In the experiments to measure the e¡ect of
putative inhibitors on the conversion rate of tracer
radioactive butyrobetaine to carnitine, the animals
were given 1.2 mmol/kg of the indicated inhibitor
BBADIS 61939 19-5-00
G.M. Fischer et al. / Biochimica et Biophysica Acta 1501 (2000) 200^210 201
(PEAA, phenylpyruvic acid and homogentisic acid)
intraperitoneally (i.p.) in 1.0 ml 0.9% NaCl solution.
Controls were injected with saline. After 30 min, all
animals were injected i.p. with approximately
1.5U107 cpm [Me-3H]butyrobetaine. At the 60th
min following the administration of the indicated
compound, and 30 min after the administration la-
beled butyrobetaine, the animals were sacri¢ced by
decapitation. Blood was collected into heparinized
tubes and the livers were rapidly removed, frozen
and stored in liquid N2 until analyses. The liver sam-
ple of animals was subjected to isotope distribution
analysis. (Due to the high speci¢c activity of the
radioactive preparatum the butyrobetaine loading
was negligible.)
In the experiments to measure the e¡ect of PEAA
on the conversion of loading amount of unlabeled
butyrobetaine, 30 min following the indicated dose
of PEAA 200 Wmol unlabeled butyrobetaine was in-
jected and 15 or 30 min following the butyrobetaine
injection the animals were sacri¢ced and their liver
and serum subjected to enzymatic analysis for total
carnitine.
In the experiments to measure the e¡ect of PEAA
on the carnitine, glutamate, K-KG levels and PEAC
formation by gas chromatograph-mass spectrometry
(GC-MS), 60 min after the above dose of PEAA the
animals were sacri¢ced and the liver and serum were
subjected to enzymatic analyses or were processed
for GC-MS analysis. In the latter experiment, two
rats were given 180 mg (1 mmol) unlabeled butyro-
betaine 5 h before sacri¢ce in order to increase liver
carnitine level.
2.4. Analyses
Free carnitine, short- and long-chain acyl-carni-
tines were determined by radioisotopic method [23]
using small columns [24], K-ketoglutarate(K-KG) [25]
and L-glutamate [26] were determined in liver sam-
ples by standard enzymatic analyses.
Distribution of radioactivity between carnitine and
butyrobetaine was evaluated by reversed-phase ion-
pairing high-performance liquid chromatography
(HPLC) as previously described [27,28]. In this
case, carnitine esters were hydrolyzed in the sample
processing. Butyrobetaine was determined by enzy-
matic analysis, involving the same HPLC separation
[27,28]. The computerized HPLC system (TOSOH,
TSK-6011) consisted of a low pressure gradient
pump, Supelcosil LC-18 column with 5 Wm particle
size (Supelco) and aTSK 6040 UV/VIZ detector. The
separation of butyrobetaine from carnitine was per-
formed by isocratic elution, using 0.01 M Na-hep-
tanesulfonate adjusted to pH 2.5 with phosphoric
acid and containing 7% methanol as eluent. The
£ow rate was 1.0 ml/min, the elution was monitored
at 210 nm and 1.0 ml fractions were collected into
scintillation vials.
2.5. Identi¢cation of phenacetyl-carnitine (PEAC) by
HPLC
In this case, the samples were processed to retain
carnitine esters as previously described [29]. The
HPLC apparatus was as detailed above. The separa-
tion of carnitine from carnitine esters was performed
by gradient elution. Solvent A was 0.01 M Na-hep-
tanesulfonate adjusted to pH 2.5 with phosphoric
acid, solvent B composed of 20% solvent A and
80% methanol. The indicated gradient (Fig. 4) was
developed from solvent A and B by a low pressure
gradient controller. Again, the £ow rate was 1.0 ml/
min, the elution was monitored at 210 nm and 1.0 ml
fractions were collected in scintillation vials.
The animals were given 5U107 cpm labeled buty-
robetaine and 5 h later, 1.2 mmol/kg of PEAA was
injected (by this time all radioactive butyrobetaine
was converted to L-carnitine and the whole body
carnitine pool has become labeled). One hour follow-
ing the administration of PEAA, the animals were
sacri¢ced. The neutralized perchloric acid extract of
liver (2.0 ml representing 250 mg original tissue) was
applied to and puri¢ed on a Dowex 50W NH/Dow-
ex 1 F3 combined ion exchange column as previ-
ously described [28,29]. The ¢nal eluate was evapo-
rated to dryness by vacuum centrifugation, using a
Speed-Vac apparatus, taken up in absolute 320‡C
methanol, centrifuged, the clear supernatant was
evaporated again and the residue was taken up in
200 Wl HPLC solvent A. In this sample, the radio-
activity was checked and 100 Wl aliquot (representing
125 mg tissue) was injected into the HPLC equip-
ment. The radioactivity and the retention time of
the fractions were compared to the to the retention
time of the authentic compounds (L-carnitine, acetyl-
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carnitine, PEAC) as detected by the UV detector at
210 nm.
2.6. Identi¢cation of PEAC by GC-MS
The neutralized perchloric acid extract of liver of
PEAA-treated rats (1.2 ml representing 150 mg tis-
sue) or 5 ml urine of PKU patients were puri¢ed on
resin and PEAC was detected as described [30] with
some modi¢cations. Brie£y, the samples were applied
to a 0.5U4 cm Dowex 50WX8 (200^400 mesh, H
form) column. Carnitine and acyl-carnitines (being
cationic compounds) were bound to the strong cati-
on-exchange resin. The column was washed with 15.0
ml 8:2 acetone:water to remove free PEAA (it was
checked that no free PEAA was retained on the col-
umn). Carnitine and acyl-carnitines were hydrolyzed
and eluated with 9.0 ml of 2 M ammonium hydrox-
ide in 50% eternal. The acyl moiety of carnitine es-
ters, such as the PEAA, were derivatized to methyl
ester for detection. Derivatization was performed in
100 Wl methanol^HCl; in a glass-capped tube by
heating at 60‡C for 1 h followed by neutalization
with 1 N KOH and centrifugation. Usually 1 Wl of
the clear supernatant was applied to the injector with
splitless mode. The GC-MS was a Shimadzu QP2000
electron ionizing equipment with quadrupole detec-
tor. A Hewlet-Packard 19091B-005 25 mU0.2 mm
capillary column covered by 0.11 Wm thick Ph-Me
Silicon was used. The injector temperature was
280‡C, the oven temperature program was as fol-
lows: 72‡C for 2 min, 72^280‡C with 15‡C/min ve-
locity, 280‡C for 3 min. The £ow rate of carrier He
gas was 1.0 ml/min. Essentially, cation-bound acids
are determined, which after this process are generally
acknowledged as acyl moiety of carnitine ester [30].
In this work, additional evidences have been supplied
that PEAA eluated with alkaline solution was previ-
ously bound to carnitine.
2.7. Statistical analyses
The values are presented as means þ S.E.M. and
were subjected to a Student’s paired t-test.
3. Results
3.1. Rate of conversion of butyrobetaine to L-carnitine
The conversion of butyrobetaine to L-carnitine
takes place via the action of the Q-butyrobetaine
hydroxylase enzyme located in the soluble fraction
of the cytosol in the liver of rats. When the conver-
sion rate of radioactive butyrobetaine was studied
(Fig. 1), by the 30th min following administration
of [Me-3H]butyrobetaine 30^35% of the injected ra-
dioactivity (4.5^5.0U106 cpm) was recovered in the
whole liver and 60^70% of this activity was found in
carnitine in control animals, in accordance with pre-
vious studies [28,31]. This amount can reasonably be
assumed as tracer due to the high speci¢c activity of
the injected labeled butyrobetaine. As Fig. 1 shows,
of the investigated compounds in the indicated dose
PEAA reduced most markedly the conversion of
[Me-3H]butyrobetaine, from the 61.3 þ 6.51 to
39.3 þ 6.00% (mean þ S.E.M., P6 0.01). Therefore,
Fig. 1. E¡ect of metabolites of phenylalanine catabolism on the
conversion of [Me-3H]butyrobetaine to [Me-3H]carnitine in the
liver of rats. The animals were given 1.2 mmol/kg of the indi-
cated compound 60 min before sacri¢ce. The samples were
processed for separation of [Me-3H]carnitine from [Me-3H]-
butyrobetaine. In 100 Wl HPLC solvent A approximately
1U105 cpm radioactivity was injected to the HPLC, of which
95% was recovered in the peaks of carnitine and butyrobetaine.
Bars indicate percentage of total (butyrobetaine plus carnitine)
radioactivity in carnitine (means þ S.E.M.) for ¢ve animals.
*P6 0.02; **P6 0.01.
BBADIS 61939 19-5-00
G.M. Fischer et al. / Biochimica et Biophysica Acta 1501 (2000) 200^210 203
in the subsequent work the e¡ect and mechanism of
action of PEAA were studied in details.
In addition to the tracer experiments (Fig. 1), the
inhibition of the £ux through butyrobetaine hy-
droxylase by PEAA was con¢rmed by using loading
amount of unlabeled butyrobetaine. As shown on
Fig. 2, the increment of liver and plasma total carni-
tine, evoked by butyrobetaine was dramatically re-
duced by PEAA. Butyrobetaine alone increased total
carnitine level in the liver from the 229 þ 10.5 nmol/g
control level to 336 þ 25.2 or to 416 þ 31.1 nmol/g by
15 and 30 min, respectively. When PEAA was ad-
ministered 30 min earlier, butyrobetaine could in-
crease the carnitine level only to 246 þ 15.1 or
316 þ 27.3 nmol/g, respectively. The calculated syn-
thesis rates from this amount of exogenous butyro-
betaine were reduced from 7.13 to 1.13 Wmol/min/g
liver during the ¢rst 15 min and from 6.23 to 2.90
Wmol/min/g during the ¢rst 30 min. The same trend
was valid for the plasma levels (Fig. 2).
3.2. Carnitine and carnitine ester levels
The changes of carnitine levels in the liver and
plasma on the e¡ect of PEAA are summarized in
Table 1. In this case, no exogenous precursor was
administered; thus, the results re£ect the synthesis
rate during 60 min from endogenous sources. Carni-
tine and its esters were measured by enzymatic anal-
ysis as in Fig. 2. As Table 1 shows, total carnitine
slightly decreased in the liver, while a redistribution
in the composition of fractions took place, namely, a
decreased free carnitine was partly compensated by
an increasing short chain carnitine esters. The plasma
total carnitine also decreased as in the liver, support-
ing the former data (Figs. 1 and 2), suggesting a
reduced rate of carnitine biosynthesis on the e¡ect
of PEAA.
3.3. Mechanism for action of PEAA
It was tested and found that PEAA in vitro did
not directly inhibit the butyrobetaine hydroxylase
enzyme (data not shown). Therefore, PEAA likely
Fig. 2. E¡ect of phenylacetate on the conversion of loading
amount of unlabeled butyrobetaine to carnitine. The animals in
the control and Bu group were given saline and those in the
Bu+PEAA group were given or 1.2 mmol/kg PEAA. Thirty
minutes later, the control group was given saline again, while
the Bu and the Bu+PEAA group were given 200 Wmol unla-
belled butyrobetaine. The animals in the latter groups were sac-
ri¢ced 15 or 30 min following the butyrobetaine injection. Sam-
ples were subjected to enzymatic analysis for total carnitine.
Bars indicate nmol carnitine in g liver or in ml plasma (means
þ S.E.M.) for six or ¢ve animals. Bu, butyrobetaine; PEAA,
phenylacetic acid. *P6 0.01, when compared to the group given
only butyrobetaine.
Table 1
E¡ect of phenylacetic acid on carnitine and carnitine ester content of plasma and liver in rats
Animals Liver carnitine (nmol/g) Plasma carnitine (nmol/ml)
Total Free SCh LCh Total Free SCh LCh
Control (n = 5) 292 þ 15.1 186 þ 18.2 82.2 þ 8.11 23.7 þ 3.20 55.2 þ 3.50 36.6 þ 4.11 13.6 þ 2.01 5.01 þ 0.41
PEAA (n = 5) 262 þ 9.86* 89 þ 10.1** 140 þ 10.2** 33.7 þ 2.31 41.6 þ 2.21* 24.1 þ 3.22* 13.2 þ 1.41 4.20 þ 0.32
The rats were given 1.2 mmol/kg of each compound i.p. and killed 60 min later. Numbers are mean þ S.E.M. for number of animals
shown in parentheses. Abbreviations: SCh, short chain carnitine ester; LCh, long chain carnitine ester; PEAA, phenyl acetic acid.
*P6 0.02; **P6 0.01
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acts in situ in a rather complex way, a¡ecting the co-
factors of butyrobetaine hydroxylase, namely K-KG
and/or ascorbic acid. In the next experiments, we
tested if the levels of co-factors required for butyro-
betaine hydroxylase were a¡ected by PEAA. We
found a signi¢cant decrease in the level of K-KG,
as well as in the level of L-glutamate (Fig. 3). (The
simultaneous changes of the two substrates could be
expected, because those are partner substrates in a
transaminase and in the glutamate dehydrogenase
reactions.) The ascorbic acid level did not change
(not shown).
3.4. Evidence for the existence of PEAC in the liver of
PEAA-treated rats
It was reported that administration of benzoic
acid, an analogue to PEAA, resulted in the forma-
tion of benzoyl carnitine in humans [13,14]. Likewise,
it was seen in Table 1, that the ratio of the short
chain carnitine ester fraction increased within the
total carnitine pool of the liver on the e¡ect
PEAA-treated rats. These ¢ndings led us to investi-
gate, whether PEAC was formed under our experi-
mental condition, contributing to the increased short
chain carnitine ester fraction.
For identi¢cation of PEAC by HPLC, the carni-
tine pool of the animals was tritium pre-labeled by
administrating high activity of [Me-3H]butyrobetaine
which was completely converted to [Me-3H]carnitine
by the time of termination of the experiment. The
retention times of authentic preparations were de-
¢ned by monitoring the OD at 210 nm (Fig. 4A).
In the radioactive elution pro¢le of a sample from
Fig. 3. E¡ect of phenylacetic acid on the glutamate and K-keto-
glutarate levels in rat liver. The control and treated animals
were given saline or 1.2 mmol/kg PEAA, respectively, 60 min
before sacri¢ce. Samples were subjected to enzymatic analysis
for L-glutamate and K-ketoglutarate. Bars indicate means
þ S.E.M. for ¢ve animals. *P6 0.01; **P6 0.02.
Fig. 4. Identi¢cation of phenacetyl-carnitine by HPLC in rat
liver. (A) Elution pro¢le of the standard preparations on
HPLC. In 100 Wl solvent A, 100 Wg carnitine (Car), 100 Wg ace-
tyl-carnitine (AcCar) and 10 Wg phenacetyl-carnitine (PEAC)
were solved and injected. Methanol (Met) gradient was as
shown. PEAA, free phenylacetic acid deriving from the PEAC
preparation. (B) A representative radioactive elution pro¢le of a
sample from a control rat carnitine pool prelabeled with triti-
um, using. [Me-3H]butyrobetaine. In solvent A, 100 Wl sample
containing 1.2U105 cpm and (representing 125 mg tissue) was
injected into the equipment and 1.05U105 cpm were recovered
in the indicated peaks. (C) A representative radioactive elution
pro¢le of a sample of a rat treated as that in item B, plus re-
ceiving 1.2 mmol/kg PEAA 1 h before sacri¢ce. In solvent A,
100 Wl sample containing 1.0U105 cpm was injected into the
equipment and approximately 9.2U104 cpm were recovered in
the indicated peaks.
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a control animal (Fig. 4B), of the applied 1.2U105
cpm radioactivity, 71 000, 29 000 and 5000 cpm were
de¢ned as free carnitine, acetyl-carnitine and pro-
pionyl-carnitine, respectively. (Although propionyl-
carnitine standard was not used here, we can reason-
ably consider the small peak as propionyl-carnitine,
based on our former experiments [27].) As a result of
a same separation of a sample containing 1.0U105
cpm radioactivity from a rat given PEAA (Fig. 4C),
we also detected 33 900, 39 700 and 4900 cpm as free
carnitine, acetyl-carnitine and propionyl-carnitine,
respectively. Additionally, in this sample, we detected
a 13 900 cpm peak far from the former ones, corre-
sponding to PEAC, according to its retention time.
The changes in the composition of carnitine fractions
on the e¡ect of PEAA (Fig. 4) are in accordance with
the data of Table 1, demonstrating a decreased free
and increased short chain carnitine ester levels.
The presence of PEAC in the liver of PEAA-
treated rats was also veri¢ed by an independent
method using gas chromatography to separate cati-
on-bound PEAA and mass spectrometry (GC-MS)
to detect it (Fig. 5, Table 2). To con¢rm that the
cation-bound PEAA was really carnitine, we in-
creased the carnitine level in liver of rats and found
that the amount of cation-bound PEAA dramatically
increased as indicated by the mass intensity of the
characteristic peaks (Table 2).
3.5. Carnitine status of the patients with PKU
The carnitine metabolism in PKU patients was
studied earlier [32^34] and the observed carnitine de-
¢ciency was partly attributed to a reduced dietary
intake. The patients in our study were not on any
Fig. 5. Identi¢cation of PEAC by GC-MS in rat liver. The ¢g-
ure shows a representative total ion chromatogram (A) and the
mass spectra of PEAA (B) obtained in the alkaline (NH4) elu-
ate of a sample of liver of a rat treated with 1.2 mmol/kg
PEAA. The sample was passed through the procedure detailed
in Section 2. The arrow (A) shows the PEAA peak and its
mass spectrum is presented in B together with an explanatory
chemical structure and fragmentation scheme.
Table 2
Formation of PEAC in the liver of rats treated with PEAA
Animals Liver total carnitine (nmol/g) Mass intensity
91 (arbitrary units) 150 (arbitrary units)
PEAA (n = 5) 192 þ 2.01 2350 þ 405 446 þ 71
PEAA plus Bu
animal I 525 8580 1870
animal II 482 7140 1428
Five rats were given 1.0 ml saline i.p. (PEAA group) and another two 1 mmol Bu in 1.0 ml saline (PEAA plus Bu group) 5 h before
sacri¢ce. One hour before sacri¢ce, all animals were given 1.2 mmol/kg of PEAA. Of the 100 Wl neutralized methanol^HCl sample
(representing 125 mg original liver tissue), 1 Wl was injected into the injector of GC-MS equipment. For more details see Section 2.
Abbreviations: PEAC, phenacetylcarnitine; PEAA, phenyl acetic acid; Bu, butyrobetaine.
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diet. Fig. 6 shows reduced total plasma carnitine
levels in PKU patients compared to healthy age-
matched controls (32.6 þ 1.51 nmol/ml vs. 43.3 þ
2.11 nmol/ml, means þ S.E.M., P6 0.01). The low-
ered plasma levels might be a consequence of an
enhanced carnitine loss with urine. However, as
Fig. 6 also shows, the urinary carnitine excretion
was also reduced in 15 of the 19 patients, and in 8
patients, it was severely (6mean33 S.D.) reduced.
For comparison, we compiled data from ¢ve other
patients on strict diet and found a further decrease in
serum carnitine to 22.1 þ 1.02 nmol/ml.
3.6. Evidence for the existence of PEAC in the urine
of patients with PKU
Since PEAA is a major component of pathological
catabolic product of phenylalanine in PKU patients,
the formation of PEAC can be expected, like in the
PEAA-treated rats. The analysis by the GC-MC
method detected PEAC in the urine of seven out of
seven patients (Table 3). As in the case of rat liver
(Table 2), to con¢rm that the detected PEAA was
really bound to carnitine, we pretreated the patient
with L-carnitine and found that a dramatically in-
creased amount of carnitine in the urine was accom-
panied by a marked increase in the intensity of mass
peaks characteristic for PEAA (Table 3). In the urine
of a healthy control subject, 30^40 times less PEAA
was detected than in the PKU patients, and no
PEAC was found (data not shown).
Fig. 6. Carnitine levels in the plasma and urine of patients with
PKU. Urine and plasma of eight controls (four male and four
female) and of 19 PKU patients (ten male, nine female) were
analyzed. Plasma: bars indicate means þ S.D. *P6 0.01. Urine:
each circle represents total carnitine of an individual person
(open circles for control subjects, closed circles for PKU pa-
tients).
Table 3
Detection of phenacetylcarnitine in the urine of PKU patients before and after carnitine supplementation
Patients Before supplementation After supplementation
Total carnitine
(nmol/ml)
Mass intensity Total carnitine
(nmol/ml)
Mass intensity
91
(arbitrary units)
150
(arbitrary units)
91
(arbitrary units)
150
(arbitrary units)
1 (m) 31.2 7 100 1 420 384 11 200 2 240
2 (m) 56.8 4 000 840 248 9 200 1 932
3 (m) 56.0 3 300 627 816 12 300 2 398
4 (f) 526 3 500 735 699 9 800 2 058
5 (f) 21.2 6 900 1 380 536 13 600 2 652
6 (m) 25.7 3 760 789 220 9 800 2 056
7 (f) 18.1 3 380 709 826 11 900 2 320
Patients were supplemented orally with 1 g L-carnitine daily for 6 days. m, male; f, female.
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4. Discussion
Earlier we reported that benzoic acid inhibited car-
nitine biosynthesis in rats [12]. In this work, we
found that of three benzoic acid analogue com-
pounds, accumulating in impaired phenylalanine me-
tabolism, PEAA was the most e¡ective in inhibiting
carnitine biosynthesis. For the mechanism of action
we propose that PEAA lowered L-glutamate level
and, in turn, the level its partner substrate K-KG,
an essential coenzyme for butyrobetaine hydroxylase
in the liver, in the only place where this enzyme
occurs (Fig. 3). The change from 136 nmol/g control
level to 109 nmol/g (from 181 to 145 Wmol/l), can be
very e¡ective in lowering the £ux through the enzyme
because this range falls below the saturation level [8].
In the case of rat liver butyrobetaine hydroxylase, a
0.5 mmol/l apparent Km value was reported for KKG
[8]. It should also be considered, that these values
were found in the whole cell. The changes in the
cytosol, where the butyrobetaine hydroxylase is lo-
cated, may be more marked.
The e¡ect of PEAA on carnitine biosynthesis in
the animal experiments led us to investigate carnitine
metabolism in PKU patients having a disorder in
phenylalanine catabolism, leading to the accumula-
tion of products such as PEAA. In our PKU patients
on an unrestricted diet, the lower plasma levels were
coupled to a markedly lowered urinary excretion of
carnitine, suggesting a severely reduced carnitine sup-
ply either from endogenous or exogenous source.
Bohles H. et al. [32] compared serum carnitine levels
in PKU patients with strict diet and on ‘o¡ diet’. In
the former group they found severe decreased, (19.4
nmol/ml) carnitine level, close to our data of patients
on diet (22.1 nmol/ml). In this group of patients the
carnitine de¢ciency was certainly caused by the re-
duced dietary intake. Some inhibitory e¡ect of
PEAA was unlikely because the PEAA level also
decreased due to the diet.
We found a less (32.6 nmol/ml, Fig. 6), but signi¢-
cant decrease in serum carnitine level of our patients
on unrestricted diet when compared to healthy con-
trols, too. Bohles et al. [32] also found a reduced
level (29.6 nmol/ml) in their patients being ‘o¡
diet’. A question is, how did the relative carnitine
de¢ciency develop in this group of patients who sup-
posedly had normal exogenous supply. Based on our
animal studies, one possibility is an inhibitory e¡ect
of PEAA on the biosynthesis, which remains to be
established by further experiment. Noteworthy, ben-
zoic acid, a close analogue to PEAA also causes
carnitine de¢ciency in man when used in therapy
[13,14].
A possible mechanism of PEAA in impairing car-
nitine biosynthesis in humans is, that PEAA, unlike
in rats, conjugates with L-glutamine[35], shuttling it
away from the glutaminase reaction, lowering the L-
glutamate formation and, in turn, K-KG level in the
liver.
The increased acyl-carnitine level in the liver of
PEAA-treated rats and a report about existence of
benzoyl-carnitine in humans [13,14] reasoned to in-
vestigate the possible formation of PEAC. We could
detect PEAC in the liver of PEAA-treated rats by
radioactive tracer method followed by HPLC sepa-
ration (Fig. 4), by GC-MS after a special resin treat-
ment (Fig. 5) supported by demonstrating quantita-
tive data (Table 2). From the elution pro¢le of
HPLC separation (Fig. 4), the PEAC can be quanti-
¢ed as approximately 15% of total carnitine in the
liver of PEAA-treated rats. By the GC-MS, a quan-
titative estimation was also possible, using a calibra-
tion curve and with calculating with mass intensity of
areas under peaks. According to this, a 18^20% of
total carnitine (47^52 nmol/g) was in form of PEAA,
which is in a fair agreement with the HPLC data. As
Table 1 shows, the short chain carnitine ester frac-
tion in total carnitine increased from 28 to 53% (by
52.8 nmol/g) on the e¡ect PEAA in rat liver. Taken
together, the PEAC formed can account for the in-
crease in short chain carnitine ester in the live rat.
Regarding the distribution of injected PEAA, 0.5^
1.0% was estimated to be in the form of carnitine
ester.
In the urine of PKU patients, the PEAC was also
detected by GC-MS. A quantitative estimation re-
vealed that from patient to patient, 5^10% of urine
total carnitine was in the form of PEAC (Table 3,
before carnitine treatment), while less than 1% of
urine PEAA formed carnitine ester. As can also be
seen, after carnitine supplementation, the intensity of
the characteristic peaks markedly increased.
The existence of benzoyl-carnitine in humans
[13,14] and phenacetyl-carnitine in rats and humans
(this work) indicates that a carnitine acyl-transferase
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having activity with aromatic CoA esters must exist,
which was not yet recognized. Characterization of
this novel enzyme (or enzyme activity) remains to
be done.
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